Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Prognosis in Primary Myelofibrosis Patients According to Cytogenetic and Molecular Testing Results

Liubov Polushkina, Irina Martynkevich, DSc, Vasily Shuvaev, MD, Mikhail Fominykh, MD, Dzhariyat Shikhbabaeva, MD, Ekaterina Motyko, PhD, Lyudmila Martynenko, Natalya Cybakova, PhD, Marina Ivanova, MD PhD, Elena Shabanova, Anastasya Zhernyakova, Alsu Savrilova, Kudrat Abdulkadyrov, Prof., MD PhD

Blood (2016) 128 (22): 5467.

https://doi.org/10.1182/blood.V128.22.5467.5467

Published: 2016

Journal Articles

The Devil Is Not As Black As He Is Painted - 3-Year Experience of Treating Newly Diagnosed CML Patients with Imatinib Generics

Vasily Shuvaev, MD, Mikhail Fominykh, MD, Vera Udaleva, MD, Irina I Zotova, MD, Regina Golovchenko, MD PhD, Dzhariyat Shikhbabaeva, MD, Irina Martynkevich, DSc, Lyudmila Martynenko, Marina Ivanova, MD PhD, Natalya Tsybakova, PhD, Ekaterina Motyko, PhD, Lyubov Polushkina, MD, Nadezhda Potikhonova, MD PhD, Sophya Tyranova, MD PhD, Marina Zenina, MD PhD, Kudrat Abdulkadyrov, MD PhD

Blood (2016) 128 (22): 5441.

https://doi.org/10.1182/blood.V128.22.5441.5441

Published: 2016

Journal Articles

It Is Safe to Change Horses in the Midstream - 3-Year Experience of Treating CML Patients with Imatinib Generics

Blood (2016) 128 (22): 5442.

https://doi.org/10.1182/blood.V128.22.5442.5442

Published: 2016

Journal Articles

Aplastic Anemia Associated with PNH-Clone - a Single Centre Experience

Elena Shilova, MD PhD, Tatiana Glazanova, MD Dr.Sci, Zhanna Chubukina, PhD, Lubov Stelmashenko, MD PhD, Sergey Gritsaev, MD Dr.Sci, Mikhail Fominykh, MD, Kudrat Abdulkadyrov, Prof., MD PhD

Blood (2016) 128 (22): 5080.

https://doi.org/10.1182/blood.V128.22.5080.5080

Published: 2016

Journal Articles

Minimal Residual Disease in Multiple Myeloma Patients: Influence on Indicators of Progression Free Survival

Andrei Garifullin, Sergei Voloshin, Irina Martynkevich, DSc, Alexey Kuvshinov, Elizaveta Kleina, Vasily Shuvaev, MD, Kudrat Abdulkadyrov, Prof., MD PhD

Blood (2016) 128 (22): 5705.

https://doi.org/10.1182/blood.V128.22.5705.5705

Published: 2016

Journal Articles

Final Results from the Phase 3 Traial Areta Comparing a Novel, Extended-Release Anagrelide Formulation to Placebo in Essential Thrombocythemia Patients with Defined Risk Status

Heinz Gisslinger, MD, Christoph Klade, Kudrat Abdulkadyrov, MD, Slawomira Kyrcz-Krzemien, MD PhD, Elena Karyagina, MD, Anait L. Melikyan, MD PhD, Krzysztof Warzocha, Barbara Grohmann-Izay, MD, Juri Hodisch, MD, Rudolf S. Widmann, PhD BSc, Robert Kralovics, Petro E. Petrides, MD PhD, Jiri Schwarz, MD PhD, Jean-Jacques Kiladjian, MD PhD

Blood (2016) 128 (22): 476.

https://doi.org/10.1182/blood.V128.22.476.476

Published: 2016

Journal Articles

Influence of JAK2V617F Allele Burden on Hematological Response in the Treatment of Polycythemia Vera

Dzhariyat Shikhbabaeva, MD, Vasily Shuvaev, MD, Regina Golovchenko, MD PhD, Vera Udaleva, MD, Mikhail Fominykh, MD, Irina I Zotova, MD, Lyubov Polushkina, MD, Irina Martynkevich, DSc, Kudrat Abdulkadyrov, MD PhD

Blood (2016) 128 (22): 5475.

https://doi.org/10.1182/blood.V128.22.5475.5475

Published: 2016

Journal Articles

Impact of Simultaneous Presence of Additional Chromosome Aberrations and BCR-ABL1 Kinase Domain Mutations on Survival in Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors

Mikhail Fominykh, MD, Vasily Shuvaev, MD, Irina Martynkevich, DSc, Oleg Shukhov, MD, Ekaterina Chelysheva, MD, Anna G Turkina, Prof., MD, Kudrat Abdulkadyrov, Prof., MD PhD

Blood (2016) 128 (22): 5437.

https://doi.org/10.1182/blood.V128.22.5437.5437

Published: 2016

Journal Articles

Efficacy of Tyrosine Kinase Inhibitors in Third Line Therapy in Chronic Phase Chronic Myeloid Leukemia

Elza Lomaia, MD PhD, Andrey Zaritskey, MD, Vasily Shuvaev, MD, Irina Martynkevich, MD PhD, Mikhail Fominykh, MD, Ekaterina Ovsyannikova, MD, Natalia Lazorko, MD, Natalia Matyuhina, MS, Pavel Butylin, PhD, Elena Machyulaitene, MD, Evgenia Salamatova, MD, Kudrat Abdulkadyrov, MD PhD

Blood (2015) 126 (23): 4051.

https://doi.org/10.1182/blood.V126.23.4051.4051

Published: 2015

Journal Articles

The Impact of Genetic Abnormalities (GA) and Other Factors on Survival in Patients after 65 Years with Multiple Myeloma (MM)

Andrei Garifullin, Irina Martynkevich, MD PhD, Sergei Voloshin, Alexei Kuvshinov, Ludmila Martynenko, Elizaveta Kleina, Galina Salogub, Elena Karyagina, Alexander Schmidt, Kudrat Abdulkadyrov

Blood (2015) 126 (23): 5314.

https://doi.org/10.1182/blood.V126.23.5314.5314

Published: 2015

Journal Articles

The Frequency of Genetic Anomalies According to Clonal Plasma Cells' Phenotype in Patients with Newly Diagnosed (ND) Multiple Myeloma (MM)

Andrei Garifullin, Irina Martynkevich, MD PhD, Sergei Voloshin, Alexei Kuvshinov, Ludmila Martynenko, Elizaveta Kleina, Kudrat Abdulkadyrov

Blood (2015) 126 (23): 5316.

https://doi.org/10.1182/blood.V126.23.5316.5316

Published: 2015

Journal Articles

Health-Related Quality of Life and Patient-Reported Outcomes in Patients Receiving Ofatumumab in Combination with Fludarabine and Cyclophosphamide (FC) Versus FC Alone in the Complement 2 Trial

Tadeusz Robak, MD Professor, Krzysztof Warzocha, MD PhD, K Govind Babu, Yaroslav Kulyaba, Kazimierz Kuliczkowski, Kudrat Abdulkadyrov, MD PhD, Javier Loscertales, Iryna Kryachok, Janusz Kloczko, Grygoriy Rekhtman, Wojciech Homenda, Jerzy Blonski, Astrid McKeown, PhD, Chai-Ni Chang, Stephanie C Manson, Steen Lisby, Ira V. Gupta, MD, Sebastian Grosicki, MD PhD

Blood (2015) 126 (23): 5288.

https://doi.org/10.1182/blood.V126.23.5288.5288

Published: 2015

Journal Articles

Pharmacoeconomical Analysis of Chronic Myelogenous Leukemia Treatment Free Remission

Vasily Shuvaev, MD, Kudrat Abdulkadyrov, MD PhD, Anna Turkina, Prof., MD, Irina Martynkevich, MD PhD, Ekaterina Chelysheva, MD PhD, Mikhail Fominykh, MD, Valentin Martchenko

Blood (2015) 126 (23): 3293.

https://doi.org/10.1182/blood.V126.23.3293.3293

Published: 2015

Journal Articles

The Rate of Individual BCR-ABL Decline As an Optimized Predictor of Tyrosine Kinase Inhibitors Treatment Outcome in Chronic Phase CML Patients, Comparison with CML Prognostic Scores and Early Molecular Response Achievement

Blood (2015) 126 (23): 5150.

https://doi.org/10.1182/blood.V126.23.5150.5150

Published: 2015

Journal Articles

The Influence of Hemostasis Genetic Features on Thrombosis Rates in Patients with Polycythemia Vera

Dzhariyat Shikhbabaeva, Vasily Shuvaev, MD, Sergey Kapustin, PhD, Irina Martynkevich, MD PhD, Vera Udaleva, MD, Regina Golovchenko, MD, Tatyana Zamotina, Mikhail Fominykh, MD, Irina Zotova, Lyubov Polushkina, Kudrat Abdulkadyrov, MD PhD

Blood (2015) 126 (23): 5180.

https://doi.org/10.1182/blood.V126.23.5180.5180

Published: 2015

Journal Articles

The Frequency of Occurrence of Minimal Residual Disease into Different Prognostic Groups of Patients with Chronic Lymphocytic Leukemia

Aleksei Kuvshinov, Sergei Voloshin, Irina Martynkevich, MD PhD, Ludmila Martynenko, Andrei Garifullin, Elizaveta Kleina, Kudrat Abdulkadyrov

Blood (2015) 126 (23): 5275.

https://doi.org/10.1182/blood.V126.23.5275.5275

Published: 2015

Journal Articles

Phenotypic Characteristics of Tumor Cells in Patients with Chronic Lymphocytic Leukemia into Different Prognostic Groups

Aleksei Kuvshinov, Sergei Voloshin, Irina Martynkevich, MD PhD, Ludmila Martynenko, Andrei Garifullin, Elizaveta Kleina, Kudrat Abdulkadyrov

Blood (2015) 126 (23): 5276.

https://doi.org/10.1182/blood.V126.23.5276.5276

Published: 2015

Journal Articles

The Results of the Russian Registry of Primary Immune Thrombocytopenia (ITP) in Adults

Blood (2015) 126 (23): 4642.

https://doi.org/10.1182/blood.V126.23.4642.4642

Published: 2015

Journal Articles

Dose-Optimized Nilotinib (NIL) in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Final Results from ENESTxtnd Study

Timothy P. Hughes, MD MBBS, FRACP, FRCPA, Marco Aurelio Salvino, MD PhD, Ong Tee Chuan, MD, Alaa Elhaddad, MD PhD, Kudrat Abdulkadyrov, MD PhD, Jake Shortt, MD, Hang Quach, MD, Carolina Pavlovsky, MD, Vernon J. Louw, MBChB, M.MD FCP(SA), PhDHPE), Lee-Yung Shih, MD, Anna G. Turkina, MD PhD, Luis Meillon, MD, Yu Jin, MS, Sadhvi Khanna, MS, Darshan Dalal, MD PhD MPH, Jeffrey H. Lipton, MD PhD

Blood (2015) 126 (23): 344.

https://doi.org/10.1182/blood.V126.23.344.344

Published: 2015

Journal Articles

Efficacy and Safety of Dose-Optimized Nilotinib (NIL) in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTxtnd Interim Analysis

Timothy P. Hughes, MD, Eduardo Ciliao Munhoz, MD, Alaa Elhaddad, MD PhD, Ong Tee Chuan, MD, Kudrat Abdulkadyrov, MD, Jake Shortt, MD, Hang Quach, MD FRACP, FRCPA, MBBS, Carolina Pavlovsky, MD, Vernon J. Louw, MBChB, M.MD FCP(SA), PhDHPE), Luis Meillon, MD, Lee-Yung Shih, MD Professor, Anna G. Turkina, MD PhD, Jonathan Hwang, PharmD, MBA, Prasanna Kumar Nidamarthy, Darshan Dalal, MD PhD MPH, Jeffrey H. Lipton, PhD MD

Blood (2014) 124 (21): 4542.

https://doi.org/10.1182/blood.V124.21.4542.4542

Published: 2014

NARROW

Prognosis in Primary Myelofibrosis Patients According to Cytogenetic and Molecular Testing Results

The Devil Is Not As Black As He Is Painted - 3-Year Experience of Treating Newly Diagnosed CML Patients with Imatinib Generics

It Is Safe to Change Horses in the Midstream - 3-Year Experience of Treating CML Patients with Imatinib Generics

Aplastic Anemia Associated with PNH-Clone - a Single Centre Experience

Minimal Residual Disease in Multiple Myeloma Patients: Influence on Indicators of Progression Free Survival

Final Results from the Phase 3 Traial Areta Comparing a Novel, Extended-Release Anagrelide Formulation to Placebo in Essential Thrombocythemia Patients with Defined Risk Status

Influence of JAK2V617F Allele Burden on Hematological Response in the Treatment of Polycythemia Vera

Impact of Simultaneous Presence of Additional Chromosome Aberrations and BCR-ABL1 Kinase Domain Mutations on Survival in Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors

Efficacy of Tyrosine Kinase Inhibitors in Third Line Therapy in Chronic Phase Chronic Myeloid Leukemia

The Impact of Genetic Abnormalities (GA) and Other Factors on Survival in Patients after 65 Years with Multiple Myeloma (MM)

The Frequency of Genetic Anomalies According to Clonal Plasma Cells' Phenotype in Patients with Newly Diagnosed (ND) Multiple Myeloma (MM)

Health-Related Quality of Life and Patient-Reported Outcomes in Patients Receiving Ofatumumab in Combination with Fludarabine and Cyclophosphamide (FC) Versus FC Alone in the Complement 2 Trial

Pharmacoeconomical Analysis of Chronic Myelogenous Leukemia Treatment Free Remission

The Rate of Individual BCR-ABL Decline As an Optimized Predictor of Tyrosine Kinase Inhibitors Treatment Outcome in Chronic Phase CML Patients, Comparison with CML Prognostic Scores and Early Molecular Response Achievement

The Influence of Hemostasis Genetic Features on Thrombosis Rates in Patients with Polycythemia Vera

The Frequency of Occurrence of Minimal Residual Disease into Different Prognostic Groups of Patients with Chronic Lymphocytic Leukemia

Phenotypic Characteristics of Tumor Cells in Patients with Chronic Lymphocytic Leukemia into Different Prognostic Groups

The Results of the Russian Registry of Primary Immune Thrombocytopenia (ITP) in Adults

Dose-Optimized Nilotinib (NIL) in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Final Results from ENESTxtnd Study

Efficacy and Safety of Dose-Optimized Nilotinib (NIL) in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTxtnd Interim Analysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only